Palvella Therapeutics (PVLA) Assets (2013 - 2026)
Palvella Therapeutics (PVLA) reported Assets of $263.8 million for Q1 2026, up 232.03% year-over-year from $79.4 million in Q1 2025, and up 342.85% on a QoQ basis from $59.6 million in Q4 2025.
Palvella Therapeutics (PVLA) has 14 years of Assets data on file, last reported at $263.8 million in Q1 2026.
- Quarterly Assets rose 232.03% year-over-year to $263.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $263.8 million (up 232.03% YoY) and the FY2025 annual result came in at $59.6 million, down 32.5% from the prior year.
- Assets climbed to $263.8 million in Q1 2026 per PVLA's latest filing, from $59.6 million in the prior quarter.
- Across five years, Assets topped out at $263.8 million in Q1 2026 and bottomed at $7.5 million in Q4 2023.
- The 5-year median for Assets is $79.4 million (2025), against an average of $81.7 million.
- The widest annual swing landed in 2023, when Assets slumped 92.1%; it then soared 1068.97% in 2024.
- Tracing PVLA's Assets over 5 years: stood at $95.5 million in 2022, then tumbled by 92.1% to $7.5 million in 2023, then soared by 1068.97% to $88.2 million in 2024, then plunged by 32.5% to $59.6 million in 2025, then jumped by 342.85% to $263.8 million in 2026.
- Per Business Quant, the three latest PVLA Assets figures stand at $263.8 million (Q1 2026), $59.6 million (Q4 2025), and $66.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 14.93 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 37.37 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.73 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 78.88 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 33.89 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 26.48 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 23.64 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 40.87 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 5.13 Bn |
| 10 | Palvella Therapeutics | 1.47 Bn | 1.21 Bn | - | 263.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 263.76 Mn |
| Dec 31, 2025 | 59.56 Mn |
| Sep 30, 2025 | 66.94 Mn |
| Jun 30, 2025 | 73.75 Mn |
| Mar 31, 2025 | 79.44 Mn |
| Dec 31, 2024 | 88.23 Mn |
| Sep 30, 2024 | 20.52 Mn |
| Jun 30, 2024 | 25.05 Mn |
| Mar 31, 2024 | 29.50 Mn |
| Dec 31, 2023 | 7.55 Mn |
| Sep 30, 2023 | 59.38 Mn |
| Jun 30, 2023 | 87.54 Mn |
| Mar 31, 2023 | 82.26 Mn |
| Dec 31, 2022 | 95.49 Mn |
| Sep 30, 2022 | 99.16 Mn |
| Jun 30, 2022 | 114.31 Mn |
| Mar 31, 2022 | 137.12 Mn |
| Dec 31, 2021 | 153.56 Mn |
| Sep 30, 2021 | 164.18 Mn |
| Jun 30, 2021 | 155.03 Mn |
| Mar 31, 2021 | 115.79 Mn |
| Dec 31, 2020 | 105.01 Mn |
| Sep 30, 2020 | 115.72 Mn |
| Jun 30, 2020 | 117.78 Mn |
| Mar 31, 2020 | 123.77 Mn |
| Dec 31, 2019 | 141.10 Mn |
| Sep 30, 2019 | 116.75 Mn |
| Jun 30, 2019 | 130.84 Mn |
| Mar 31, 2019 | 131.05 Mn |
| Dec 31, 2018 | 141.34 Mn |
| Sep 30, 2018 | 151.66 Mn |
| Jun 30, 2018 | 162.03 Mn |
| Mar 31, 2018 | 173.24 Mn |
| Dec 31, 2017 | 103.88 Mn |
| Sep 30, 2017 | 98.86 Mn |
| Jun 30, 2017 | 105.96 Mn |
| Mar 31, 2017 | 61.88 Mn |
| Dec 31, 2016 | 35.06 Mn |
| Sep 30, 2016 | 43.71 Mn |
| Jun 30, 2016 | 46.45 Mn |
| Mar 31, 2016 | 37.21 Mn |
| Dec 31, 2015 | 33.95 Mn |
| Sep 30, 2015 | 36.20 Mn |
| Jun 30, 2015 | 14.48 Mn |
| Mar 31, 2015 | 16.77 Mn |
| Dec 31, 2014 | 21.86 Mn |
| Sep 30, 2014 | 220.00 |
| Jun 30, 2014 | 11,138.00 |
| Mar 31, 2014 | 196.00 |
| Dec 31, 2013 | 7.28 Mn |
| Jun 30, 2013 | 5,200.00 |